But they also speak volumes about the value of Kite’s main scientific partner: the United States government. Kite’s treatment, a form of immunotherapy called   was initially developed by a team of researchers at the National Cancer Institute, led by a longtime friend and mentor of Dr. Belldegrun. Now Kite pays several million a year to the government to support continuing research dedicated to the company’s efforts. The relationship puts American taxpayers squarely in the middle of one of the hottest new drug markets. 